Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical company that focuses on advancing the fields of science and medicine to improve lives.

Mallinckrodt Pharmaceuticals

MNK Meetings

Opioid Dose Conversion Calculator

Acthar IS Dosing Calculator

Domain Not Resolving

Google Font API

DNSSEC

LetsEncrypt

IPv6

Apache

Apple Mobile Web App Capable

Apple Mobile Web App Status Bar Style

Japanese Yen

Java EE

Associate General Counsel - Business Development & Commercial

Babak Torgoley

Senior Vice President & Chief Communications Officer

Brandi Robinson

Executive Vice President and Chief Financial Officer

Bryan Reasons

Vice President, General Counsel of Specialty Generics

Cathi Ponciroli

Associate General Counsel - IP

Craig Siman

Chief Information Security Officer

Dan Curran

Vice President and General Counsel, Specialty Generics

Donald Lohman

Executive Vice President and Chief Human Resources Officer

Ian Watkins

General Counsel, Brands

Lars Taavola

Executive Vice President & Chief Legal Officer

Mark Casey

David Carlucci

Melvin Booth

Paul O'Neill

SVP Quality and Operations, Specialty Brands

Ryan Magee

Global Device Engineering Director of Validation and Engineering Services

Jim Shortt

Engineering Manager

Emil Mallinckrodt

Founder

Mark Trudeau

Peter Richardson

Executive Vice President and Chief Scientific Officer

Matt Harbaugh

Oliver Fay

Project Manager, ARD Program Management

Silence Therapeutics is a drug development company with a proprietary genetic medicine platform.

European Union (EU) Public Companies With More Than 10 Employees

European Union (EU) Companies With More Than $500 in Revenue

Investors Active in London, England

Europe, Middle East, and Africa (EMEA) Companies With More Than $1B in Revenue

Their evolution as a company starts now, and they are poised for an exciting future. Their core strengths provide the impetus for future success, including skills in the acquisition and management of highly regulated raw materials; strong regulatory knowledge, reputation, and relationships; distinctive manufacturing and logistics skills where vertical integration is an advantage; expertise in specialized chemistry, development, and formulation; and global commercial reach.

Blanchardstown

Dublin

Ireland

Europe

Mallinckrodt

Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt presents data on Terlivaz for injection in patients with HRS

Mallinckrodt to Present at Jefferies London Healthcare Conference

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance

Inhaled Nitric Oxide Market Expected to grow by 7.41% from 2023 to 2033 | Evolve Business Intelligence

Mallinckrodt presents data on TERLIVAZ for injection in patients with HRS

Mallinckrodt announces INOmax Evolve DS delivery system rollout

Mallinckrodt sells Therakos unit on at a discount

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

Mallinckrodt sells photopheresis platform Therakos for $925M

A naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs used for treating autoimmune disorders and inflammation-related medical conditions.

A single-dose pre-filled injection device for subcutaneous delivery of Acthar Gel, designed to improve administration for patients and caregivers.

Products focused on autoimmune and rare diseases in areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology.

Therapies aimed at treating immune system disorders and providing respiratory support for neonates.

Pain relief medications developed and marketed by Mallinckrodt.

Pharmaceuticals targeting gastrointestinal conditions.

United States

North America

Cameroon

Africa

India

Asia

Canada

HTML5

Comodo PositiveSSL Certificates

Google Maps API

Office 365

GlobalSign

Vimeo

.NET 4.5

Wordpress

Symantec Email Security.Cloud

Facebook Comments

Mallinckrodt owns BioVectra

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 28, 2024 12:46 PM	b8ff811c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 28, 2024 12:46 PM	6b1e6f0a
crunchbase trigger	general	Nov 25, 2024 9:06 AM	6debff09
crunchbase profile	general	Nov 25, 2024 10:52 AM	aae6edae
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 4:20 PM	2a62c52f
peers	general	Sep 28, 2024 12:46 PM	45dfeeb4
news basic	general	Sep 28, 2024 12:46 PM	a3ea63ab
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:MALLINCKRODT

Mallinckrodt Pharmaceuticals